JP2018505859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505859A5 JP2018505859A5 JP2017532868A JP2017532868A JP2018505859A5 JP 2018505859 A5 JP2018505859 A5 JP 2018505859A5 JP 2017532868 A JP2017532868 A JP 2017532868A JP 2017532868 A JP2017532868 A JP 2017532868A JP 2018505859 A5 JP2018505859 A5 JP 2018505859A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- treatment
- xaa
- chem
- reduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002265 prevention Effects 0.000 claims 87
- 230000009467 reduction Effects 0.000 claims 30
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 18
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 12
- 208000002705 Glucose Intolerance Diseases 0.000 claims 9
- 102000004877 Insulin Human genes 0.000 claims 9
- 108090001061 Insulin Proteins 0.000 claims 9
- 208000008589 Obesity Diseases 0.000 claims 9
- 230000001154 acute effect Effects 0.000 claims 9
- 206010012601 diabetes mellitus Diseases 0.000 claims 9
- 229940125396 insulin Drugs 0.000 claims 9
- 235000020824 obesity Nutrition 0.000 claims 9
- 201000009104 prediabetes syndrome Diseases 0.000 claims 9
- 201000006474 Brain Ischemia Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 6
- 208000011231 Crohn disease Diseases 0.000 claims 6
- 208000030814 Eating disease Diseases 0.000 claims 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 6
- 230000000747 cardiac effect Effects 0.000 claims 6
- 206010008118 cerebral infarction Diseases 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 208000029078 coronary artery disease Diseases 0.000 claims 6
- 230000003111 delayed effect Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 235000014632 disordered eating Nutrition 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000007848 Alcoholism Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 206010059245 Angiopathy Diseases 0.000 claims 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 3
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 3
- 102000007592 Apolipoproteins Human genes 0.000 claims 3
- 108010071619 Apolipoproteins Proteins 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000031729 Bacteremia Diseases 0.000 claims 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 3
- 208000018152 Cerebral disease Diseases 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 3
- 208000028399 Critical Illness Diseases 0.000 claims 3
- 208000014997 Crohn colitis Diseases 0.000 claims 3
- 208000002249 Diabetes Complications Diseases 0.000 claims 3
- 206010012655 Diabetic complications Diseases 0.000 claims 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 3
- 206010013654 Drug abuse Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000007530 Essential hypertension Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010058179 Hypertensive emergency Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 206010022562 Intermittent claudication Diseases 0.000 claims 3
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 3
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 3
- 208000035180 MODY Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010071436 Systolic dysfunction Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 206010046543 Urinary incontinence Diseases 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 3
- 206010001584 alcohol abuse Diseases 0.000 claims 3
- 208000025746 alcohol use disease Diseases 0.000 claims 3
- 230000000561 anti-psychotic effect Effects 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 235000019789 appetite Nutrition 0.000 claims 3
- 230000036528 appetite Effects 0.000 claims 3
- 230000006793 arrhythmia Effects 0.000 claims 3
- 206010003119 arrhythmia Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 3
- 208000014679 binge eating disease Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 230000036772 blood pressure Effects 0.000 claims 3
- 230000003915 cell function Effects 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000006549 dyspepsia Diseases 0.000 claims 3
- 230000037406 food intake Effects 0.000 claims 3
- 235000012631 food intake Nutrition 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 230000030135 gastric motility Effects 0.000 claims 3
- 208000004104 gestational diabetes Diseases 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 230000006872 improvement Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 201000005857 malignant hypertension Diseases 0.000 claims 3
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims 3
- 230000004060 metabolic process Effects 0.000 claims 3
- 230000004899 motility Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 208000037891 myocardial injury Diseases 0.000 claims 3
- 230000000626 neurodegenerative effect Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 230000033764 rhythmic process Effects 0.000 claims 3
- 230000036186 satiety Effects 0.000 claims 3
- 235000019627 satiety Nutrition 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 230000036303 septic shock Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 210000002784 stomach Anatomy 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 206010042772 syncope Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 230000035488 systolic blood pressure Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 208000019553 vascular disease Diseases 0.000 claims 3
- 230000002747 voluntary effect Effects 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- WLNMZODBWIWRGN-SSDOTTSWSA-N (2R)-2-amino-2-formyl-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C(=O)[C@](N)(CC1=CNC=N1)C(=O)O WLNMZODBWIWRGN-SSDOTTSWSA-N 0.000 claims 1
- OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims 1
- ACZFBYCNAVEFLC-YFKPBYRVSA-N (S)-3-(imidazol-5-yl)lactic acid Chemical compound OC(=O)[C@@H](O)CC1=CN=CN1 ACZFBYCNAVEFLC-YFKPBYRVSA-N 0.000 claims 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14198589 | 2014-12-17 | ||
| EP14198589.5 | 2014-12-17 | ||
| PCT/EP2015/080165 WO2016097108A1 (en) | 2014-12-17 | 2015-12-17 | Glp-1 derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505859A JP2018505859A (ja) | 2018-03-01 |
| JP2018505859A5 true JP2018505859A5 (enExample) | 2019-02-07 |
| JP6691125B2 JP6691125B2 (ja) | 2020-04-28 |
Family
ID=52338853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532868A Active JP6691125B2 (ja) | 2014-12-17 | 2015-12-17 | Ｇｌｐ−１誘導体及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10392428B2 (enExample) |
| EP (1) | EP3233898A1 (enExample) |
| JP (1) | JP6691125B2 (enExample) |
| CN (1) | CN107108714B (enExample) |
| WO (1) | WO2016097108A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160021183A (ko) | 2013-06-20 | 2016-02-24 | 노보 노르디스크 에이/에스 | Glp-1 유도체 및 그것의 용도 |
| CN106999602B (zh) | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| PL3393496T3 (pl) | 2015-12-23 | 2024-04-22 | The Johns Hopkins University | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| MA46780A (fr) | 2016-11-07 | 2019-09-11 | Novo Nordisk As | Esters à dchbs actif de composés peg et leur utilisation |
| SG11202002259XA (en) * | 2017-09-19 | 2020-04-29 | Immunwork Inc | Pharmaceutical constructs with enhanced binding affinity with albumin |
| PE20211417A1 (es) | 2018-04-05 | 2021-08-02 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1 |
| WO2019200594A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| WO2019201333A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | Glp-1衍生物及其治疗用途 |
| JP2023545684A (ja) | 2020-09-30 | 2023-10-31 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートおよび使用の方法 |
| TW202440619A (zh) | 2020-12-18 | 2024-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| CN116655772A (zh) * | 2022-02-18 | 2023-08-29 | 成都奥达生物科技有限公司 | 一种长效的glp-1/glp-2双激动剂化合物 |
| CA3252113A1 (en) | 2022-03-30 | 2023-10-05 | Beijing Ql Biopharmaceutical Co Ltd | Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use |
| WO2024112617A2 (en) * | 2022-11-21 | 2024-05-30 | Eli Lilly And Company | Process for preparing a gip/glp1 dual agonist |
| WO2024261319A1 (en) * | 2023-06-23 | 2024-12-26 | Imperial College Innovations Limited | Methods of chemical synthesis of peptides |
| CN117586375B (zh) * | 2024-01-19 | 2024-07-30 | 苏州金顶生物有限公司 | 一种制备司美格鲁肽的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE466027T1 (de) | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
| HUP0200297A3 (en) | 1999-03-17 | 2002-09-30 | Novo Nordisk As | Method for acylating peptides and the glutaminic acid derivatives as acylating agents |
| AU1269501A (en) | 1999-11-12 | 2001-05-30 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
| GB0020551D0 (en) | 2000-08-22 | 2000-10-11 | Birkett David | Sprinkler system |
| BR0306706A (pt) | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
| BRPI0407936A (pt) | 2003-03-19 | 2006-02-21 | Lilly Co Eli | composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado |
| CN100444898C (zh) * | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2007011307A (es) | 2005-03-18 | 2007-10-08 | Novo Nordisk As | Compuestos de glp-1 extendidos. |
| EA012442B1 (ru) | 2005-05-13 | 2009-10-30 | Эли Лилли Энд Компани | Пегилированные соединения glp-1 |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2010142665A1 (en) | 2009-06-11 | 2010-12-16 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| BR112012024379A2 (pt) | 2010-03-26 | 2017-01-10 | Novo Nordisk As | "peptídeos glucagon, seu uso, bem como composição farmacêutica" |
| WO2012012352A2 (en) | 2010-07-19 | 2012-01-26 | Amidebio, Llc | Modified peptides and proteins |
| US9708383B2 (en) | 2010-11-09 | 2017-07-18 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
| CA2832811A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| EP2723359A4 (en) | 2011-06-24 | 2015-03-11 | Amylin Pharmaceuticals Llc | METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS |
| WO2013041678A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| WO2013167454A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| KR20160021183A (ko) | 2013-06-20 | 2016-02-24 | 노보 노르디스크 에이/에스 | Glp-1 유도체 및 그것의 용도 |
| US9498534B2 (en) | 2013-07-04 | 2016-11-22 | Novo Nordisk A/S | Derivatives of GLP-1 like peptides, and uses thereof |
| CN106999602B (zh) | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| MA46780A (fr) * | 2016-11-07 | 2019-09-11 | Novo Nordisk As | Esters à dchbs actif de composés peg et leur utilisation |
-
2015
- 2015-12-17 JP JP2017532868A patent/JP6691125B2/ja active Active
- 2015-12-17 US US15/534,644 patent/US10392428B2/en active Active
- 2015-12-17 WO PCT/EP2015/080165 patent/WO2016097108A1/en not_active Ceased
- 2015-12-17 CN CN201580068403.2A patent/CN107108714B/zh active Active
- 2015-12-17 EP EP15817215.5A patent/EP3233898A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505859A5 (enExample) | ||
| JP2016523243A5 (enExample) | ||
| JP2016529253A5 (enExample) | ||
| JP2017105819A5 (enExample) | ||
| JP2019513126A5 (enExample) | ||
| JP2014529629A5 (enExample) | ||
| JP2014501712A5 (enExample) | ||
| JP2013543853A5 (enExample) | ||
| JP2018506507A5 (enExample) | ||
| US10265384B2 (en) | Tablets comprising GLP-1 agonist and enteric coating | |
| JP2023071869A (ja) | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト | |
| RU2013148921A (ru) | Дважды ацилированные производные glp-1 | |
| WO2013004983A1 (en) | Novel compounds and their effects on feeding behaviour | |
| US20220062184A1 (en) | Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating | |
| JP2015517478A5 (enExample) | ||
| JP2007519642A5 (enExample) | ||
| JP2015502918A5 (enExample) | ||
| JP2020522559A (ja) | 経口投与用固形組成物 | |
| JP2012529434A5 (enExample) | ||
| JP2015517458A5 (enExample) | ||
| CA2605847C (en) | Ddp-iv inhibitors for the treatment of postprandial hyperlipidemia | |
| JP2016526533A (ja) | アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体 | |
| JPWO2011002011A1 (ja) | Ｓｇｌｔ１阻害薬とｄｐｐ−ｉｖ阻害薬を組み合わせてなる医薬 | |
| US20250326814A1 (en) | Modified oxyntomodulin and methods of use thereof | |
| Yap et al. | Exendin-4 and Its Related Peptides |